Triastek Honored with 2023 Healthcare Application Award at the TCT Awards Ceremony – Triastek’s Melt Extrusion Deposition (MED®) 3D printing technology voted best 3D printing technology in the healthcare sector

June 08, 2023, Triastek, Inc. (“Triastek”), a global healthcare company developing medicines with proprietary, pioneering 3D printing technology, announced they have won the 2023 TCT Award for Best 3D Printed Technology in Healthcare, making it the first pharmaceutical company winning this award. There were 140 entries across the globe submitted for the awards. Over 200 people attended the awards ceremony in Birmingham, UK.

TCT Healthcare Application Award for Best 3D Printed Technology in Healthcare

TCT Awards provide recognition for innovators whose ideas help propel advancement of Additive Manufacturing. The TCT Awards is an annual celebration of outstanding innovations and applications of 3D printing and Additive Manufacturing technologies from across the globe. Launched in 2017, the awards celebrate the innovative hardware, software, materials and post-processing technologies that have been developed over the past year. Additionally commended are the incredible applications of these technologies across industry verticals including aerospace, defense, automotive, rail, consumer products, industrial products, healthcare, and the creative industries. Entries are judged by over twenty independent industry experts using a robust set of judging criteria.

The European Pharmaceutical Manufacturer commented Triastek in its May/June issue’s cover story, “The implications of Triastek’s technology, laced with the company’s ambitious vision, could potentially bring to light a technological shift that has been promised for a number of years. This shift promises not just enhancements to production efficiency, but also provides fresh solutions to complex drug delivery conundrums.”

One of the TCT Awards’ expert judging panel noted, “It is great to see this concept coming to fruition as it has been talked about for many years. The productivity of this process along with the use of FDA-approved materials is very impressive.”

“We are proud to be recognized among some of the most prominent companies with innovative 3D printing solutions for our Melt Extrusion Deposition (MED®) 3D printing technology, which we believe has the potential to transform the pharmaceutical industry,” said Dr. Senping Cheng, founder and CEO of Triastek.” We thank TCT for honoring Triastek with this prestigious award. Our commitment to innovative endeavors remains steadfast as we strive to advance the industry towards digital product development and intelligent manufacturing.”

Source: Triastek

For press release, welcome to send to 3D Science Valley at

You may also like...

Leave a Reply